Moderately Decreasing FVE After Exact Sciences Reveals Soft 2023 Outlook

Exact Sciences has a three-pronged approach to cancer testing: non-invasive Cologuard is likely to continue gaining share of colorectal cancer screening, and ongoing development of both early screening and minimum residual disease, or MRD, testing gives Exact exposure to the nascent liquid biopsy market. Exact is attempting to position itself as a winner regardless of whether liquid biopsy takes off, with Cologuard likely to remain a decent alternative to colonoscopy over the near term, while the firm’s pan-cancer and single-cancer liquid biopsy tests could offset Cologuard share loss in a scenario where liquid biopsy rapidly gains share.